

# Study Overview

## Brief Summary

This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant FR-alpha positive advanced EOC, primary peritoneal cancer and/or fallopian tube cancer.

## Detailed Description

Participants will be randomized to either mirvetuximab soravtansine or investigator's choice chemotherapy.

## Official Title

FORWARD I: A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) Versus Investigator's Choice of Chemotherapy in Women With Folate Receptor Alpha Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer

## Conditions

Epithelial Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerOvarian Cancer

## Intervention / Treatment

- Drug: Mirvetuximab soravtansine
- Drug: Paclitaxel
- Drug: Pegylated liposomal doxorubicin
- Drug: Topotecan

## Other Study ID Numbers

- IMGN853-0403

**Study Start (Actual)**

2016-03-02

**Primary Completion (Actual)**

2019-01

**Study Completion (Actual)**

2020-01

**Enrollment (Actual)**

366

**Study Type**

Interventional

**Phase**

Phase 3